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AbsTrACT
rationale asthma is characterised by inflammation and 
reversible airway obstruction. However, these features 
are not always closely related. Fluctuations of daily lung 
function contain information on asthma phenotypes, 
exacerbation risk and response to long-acting β-agonists.
Objectives in search of subgroups of asthmatic 
participants with specific lung functional features, we 
developed and validated a novel clustering approach 
to asthma phenotyping, which exploits the information 
contained within the fluctuating behaviour of twice-daily 
lung function measurements.
Methods Forced expiratory volume during the first second 
(FeV1) and peak expiratory flow (PeF) were prospectively 
measured over 4 weeks in 696 healthy and asthmatic 
school children (Protection against allergy – Study in rural 
environments (PaStUre)/eFraiM cohort), and over 1 year 
in 138 asthmatic adults with mild-to-moderate or severe 
asthma (Pan-european longitudinal assessment of clinical 
course and BiOmarkers in Severe chronic airway Disease 
(BiOair) cohort). Using enrichment analysis, we explored 
whether the method identifies clinically meaningful, distinct 
clusters of participants with different lung functional 
fluctuation patterns.
Measurements and main results in the PaStUre/
eFraiM dataset, we found four distinct clusters. 
two clusters were enriched in children with well-
known clinical characteristics of asthma. in cluster 3, 
children from a farming environment predominated, 
whereas cluster 4 mainly consisted of healthy controls. 
about 79% of cluster 3 carried the asthma-risk allele 
rs7216389 of the 17q21 locus. in the BiOair dataset, 
we found two distinct clusters clearly discriminating 
between individuals with mild-to-moderate and severe 
asthma.
Conclusions Our method identified dynamic functional 
asthma and healthy phenotypes, partly independent of 
atopy and inflammation but related to genetic markers 
on the 17q21 locus. the method can be used for disease 
phenotyping and possibly endotyping. it may identify 
participants with specific functional abnormalities, 
potentially needing a different therapeutic approach.
InTrOduCTIOn
Approaches to identifying phenotypes or endo-
types in asthma have become increasingly rele-
vant.1–7 Cluster analysis using clinical, atopic, and 
inflammatory biomarkers has facilitated pheno-
typing in selected cross-sectional asthma studies.8–12 
However, in the majority of published approaches, 
the characterising parameters are only assessed 
at a single point in time,8–18 yielding phenotypes 
that might not remain stable as time progresses.19 
Furthermore, most studies using clustering methods 
are based on predefined biomarkers that are often 
only loosely correlated with temporal changes in 
clinical symptoms or lung function. In addition, 
as opposed to atopy and inflammation, airway 
dynamics have been neglected as a characterising 
entity of asthma.20 Indeed, in asthma, both airway 
inflammation and variable airway obstruction are 
key components of this chronic disease. While 
airway inflammation and airway obstruction are 
often related, there are also mechanisms leading 
to lung functional abnormalities and asthma symp-
toms partly independent of airway inflammation 
but related to genetic factors, obesity, airway struc-
ture, and shear stress phenomena.20–22 
Key messages
What is the key question?
 ► Using a novel approach to asthma phenotyping 
based on clustering of daily lung function 
fluctuations, we aim to determine whether 
we can identify asthma patients with specific 
functional characteristics in response to the 
time-varying stimuli of the environment to 
which they are exposed.
What is the bottom line?
 ► Lung function fluctuations reveal asthma 
phenotypes that are partly independent of 
the inflammatory disease process but strongly 
related to airway mechanics and bronchodilator 
response.
Why read on?
 ► This novel, fluctuation-based clustering 
technique may help identify asthmatics with 
functional abnormalities, potentially benefitting 
from alternative therapeutic schemata, rather 
than anti-inflammatory treatment only.
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There is recent evidence of daily fluctuations in inflamma-
tory markers such as eosinophil counts,23 exhaled nitric oxide24 
and, in particular, lung function.25 The fluctuation behaviour 
of lung function contains unexpected amounts of information 
on asthma characteristics such as airway obstruction and may 
provide more accurate clues regarding phenotype stability.20 25–27 
Furthermore, time series of daily lung function measurements 
display non-random fluctuations and long-range correlation 
properties significantly related to asthma phenotype26 and to 
exacerbation risk.25 27 In addition, these seem to have predic-
tive power regarding clinical treatment response, for example, 
to long-acting β-agonists.28
Recent data suggest that in some asthma phenotypes, step-up 
treatment with long-acting β-agonists is more effective than an 
increase in anti-inflammatory treatment.29 The results shown 
in ref. 28 thus suggest that airway function and its interaction 
with environmental stimuli may characterise a specific asthma 
phenotype, which could potentially benefit from different ther-
apeutic approaches.29
We hypothesised that we could identify such subgroups of 
asthmatic participants with specific airway functional response 
to their time-varying environmental stimuli by investigating 
the patterns of fluctuation in airway function. Thus, time series 
fluctuation analysis and clustering methods could be combined, 
resulting in a novel, data-driven method for lung functional 
asthma phenotyping. We call this approach fluctuation-based 
clustering (FBC). It provides a new, complementary dimension 
for observer-independent asthma phenotyping.
Herein, we aim to determine whether FBC is able to distin-
guish children with asthma from healthy children. Furthermore, 
we tested whether different lung functional phenotypes existed 
within the groups of individuals with asthma and healthy indi-
viduals, and whether they were associated with predefined clin-
ical asthma phenotypes, environmental factors, as well as genetic 
factors and inflammatory biomarkers of asthma. We performed 
this study prospectively in the Protection Against Allergy – Study 
in Rural Environments (PASTURE)/EFRAIM cohort of asth-
matic and healthy children,30–32 in which serial measurements 
of twice-daily lung function parameters were obtained within a 
time window of four consecutive weeks.
The second dataset consisted of twice-daily lung function 
parameters measured over an entire year in a cohort of mildly/
moderately and therapy-resistant, severely asthmatic adults 
(Pan-European Longitudinal Assessment of Clinical Course 
and BIOmarkers in Severe Chronic AIRway Disease (BIOAIR) 
cohort).33 In this second independent dataset, we tested whether 
FBC could discriminate individuals with mild-to-moderate 
asthma from individuals with severe asthma. This aim was moti-
vated by our previous observations,26 namely, that severe asth-
matics show different lung function fluctuation patterns when 
compared with individuals with mild-to-moderate asthma, 
despite large variation and overlap of mean lung function 
between these two groups. The analysis of the second cohort 
was mainly done for the purpose of method validation using an 
additional independent data set and not with the intention of 
comparing the two cohorts directly.
MeThOds
Our method, comprehensively described in the online supple-
mentary material (OSM), aims to group or cluster individuals 
with similar fluctuation patterns in their lung function. To 
this end, we took into account both the mean lung function 
during the window of observation and also the magnitude and 
frequency of the fluctuations around the mean. This was accom-
plished by looking at each patient’s entire empirical distribution 
of lung function parameters obtained during the time window 
of measurement. However, in order to more easily deal with 
missing measurements, our method does not take into account 
the chronological order of the measurements. Thereby, the 
temporal dimension is neglected.
Our cluster construction procedure does not make use of 
any further clinical parameters but is solely based on either of 
the two lung function parameters, peak expiratory flow (PEF) 
and forced expiratory volume during the first second (FEV1). 
In order to test whether the clusters obtained via FBC indeed 
grouped together participants who shared meaningful clinical 
and diagnostic features, we compared the predominant clinical 
characteristics of patients in the clusters found in the cohort of 
children with previously published clinical symptoms and asthma 
phenotypes,15 in particular, with respect to atopic, inflammatory 
(fraction of exhaled nitric oxide (FeNO)) and genetic markers. 
Furthermore, in the second cohort of asthmatic adults, we tested 
whether the clusters found discriminated mild-to-moderate 
asthma from severe therapy-resistant asthma.
study design
The current proof of concept study has been prospectively 
embedded in the PASTURE/EFRAIM cohort. This is a prospec-
tive birth cohort study of children from rural areas in five Euro-
pean countries. Its design has been described elsewhere.30 31 34
Furthermore, we also illustrated our methodology using 
data from the BIOAIR study ( ClinicalTrials. gov identifier: 
NCT00555607). This study was designed to characterise the 
course of severe chronic airway diseases over time using a 
multitude of different clinical outcomes. The design has been 
described in detail elsewhere.33 Both studies were approved by 
all ethics committees of the corresponding participating study 
centres.
 Study population and definition of clinical phenotypes
Within the PASTURE/EFRAIM cohort, at the age of 6 years, 
n=799 of n=1133 asthmatic and healthy children were enrolled. 
A percentage of 51.7 of the children were born in a farming envi-
ronment. About 8.4% showed symptoms of asthma according to 
standardised assessments of clinical symptoms.30
Within the BIOAIR study, 169 adults with asthma were 
screened and classified as either severe asthmatics (n=93) or 
mild-to-moderate asthmatics (n=76).35 Patients were followed 
for 12 months with control visits at 4 monthly intervals. The 
present analysis included 138 patients (76 with severe asthma 
and 62 with mild-to-moderate asthma).
See tables in the OSM for more details.
 Lung function measurements
See Methods, and part 1.2 of OSM for details. Within the 
PASTURE/EFRAIM cohort, measurements of PEF in L/min 
and of FEV1 in L were recorded over a 4-week period at study 
participants’ homes twice-daily (morning and evening). Ideally, 
this resulted in a total of 56 home measurements per study 
participant.
Within the BIOAIR study, lung function (PEF in L/min and 
FEV1 in L) was recorded twice-daily using electronic diaries over 
a period of 12 consecutive months. Ideally, this resulted in a total 
of 730 measurements per study participant.
Measured values of PEF and FEV1 were standardised using 
recently published reference data for spirometry.36
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brief overview of the computational methodology
Two examples from the PASTURE/EFRAIM cohort of morning 
FEV1 time series are shown in figure 1A. While the mean 
values of both time series may be nearly the same, important 
and clinically relevant differences are reflected in the amplitude 
and frequency of fluctuations around the mean. Such differ-
ences become apparent by looking at the distribution of values 
(figure 1B).
Our method comprises five main steps: (1) First, after quality 
control, we select a high-quality ‘seeding’ data subset we refer to 
as the gold standard. The distribution of lung function measure-
ments of a given participant is compared with the distributions 
of all the other participants. This pair-wise comparison is done 
using the Earth Mover’s Distance (see OSM). These compari-
sons yield a collection of distance values for each participant in 
the cohort, which characterises every participant. We call these 
collections ‘lung function profiles’. (2) We perform an initial 
agglomerative hierarchical clustering of the gold standard based 
on the Euclidean distance between the participants’ lung function 
profiles. Subsequently, we determine, in a data-driven manner, 
the tolerable levels of missing values by means of analysing the 
stability of the clustering of the gold standard upon random data 
removal. (3) We extend the gold standard by including those 
participants not exceeding the tolerable levels of missing values. 
(4) We perform the final clustering of participants, and (5) we 
evaluate the method by testing whether patients within a given 
cluster exhibit specific clinical characteristics. This analysis of 
the resulting clusters, which uses information that was not used 
to inform the clustering procedure, yields criteria for selecting 
the number of clusters. (See figure 2 for a schematic represen-
tation of the method exemplified on data from the PASTURE/
EFRAIM cohort, and figure 3 for steps 1–4.)
Within the PASTURE/EFRAIM cohort, the analysis was 
conducted using the morning FEV1 measurements for the 
following reasons: evening measurements are more influ-
enced by various daytime environmental stimuli than morning 
Figure 1 FEV1 values (normalised as described in subsection 2.1 
of the online supplementary material) collected in the mornings by 
two participants during a time window of 4 weeks (PASTURE/EFRAIM 
cohort). (A) displays the values as time series. Marked differences 
in the pattern of missing values and in the total length of the time 
series become apparent. Panel (B) displays the values as histograms, 
disregarding the chronological order of the data. This representation 
reveals that both time series share a common mean value. However, 
the data are distributed very differently, displaying completely different 
fluctuation patterns. Such differences can be quantified by descriptors 
such as variance, skewness, kurtosis and higher moments of the 
distribution. PASTURE, Protection Against Allergy – Study in Rural 
Environments.
Figure 2 Workflow of the method exemplified based on data 
from the PASTURE/EFRAIM cohort. Blue rectangles: Based on quality 
and compliance criteria (see Methods section, part 2.1 of online 
supplementary material), we select a subset of participants with a 
nearly complete collection of high-quality measurements. This subset 
is used as our gold standard (size ngs). Pink rectangles: within the gold 
standard, we calculate the matrix of pairwise distances between all 
patients’ distributions of lung function measurements. Each row within 
this matrix constitutes what we call the lung function profile of each 
patient within the given cohort. We use these profiles as the phenotypic 
fingerprint of each of these patients within the context of the cohort 
and perform hierarchical clustering on the rows of the matrix (see also 
figure 3, panels A and B). On the resulting dendrogram, we then identify 
potentially suitable clusters (see also figure 3, panel A). In order to 
include those participants who had more missing values, we analyse the 
stability of the clusters upon percental data removal (see also figure 3, 
panel C). This step is what helps determine the maximal number of 
missing values allowable and enables us to extend the gold standard 
to a possibly larger subset of the cohort (size ntolerable). Green rectangles: 
for this extended selection of participants, the aforementioned matrix 
is again calculated, and a final dendrogram is obtained on the basis of 
hierarchical clustering of the matrix rows (see also figure 3, panel D). 
Red rectangle: we evaluate the method by testing whether the clusters 
found are significantly enriched in clinical phenotypes or characteristics 
of interest. More details on each step can be found in the Methods 
section and in the OSM. PASTURE, Protection Against Allergy – Study in 
Rural Environments.
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measurements. Furthermore, during the measurement in chil-
dren, PEF may still be slightly more dependent on cooperation 
than FEV1. Lastly, in many randomised controlled trials, FEV1 
is still the most often used outcome parameter. The results 
obtained using other combinations of lung function parameters 
(PEF or FEV1) and time slots (morning, evening and entire day) 
can be found in the OSM for the sake of illustration.
resulTs
In the application and evaluation of our method, the results 
are generated according to the FBC methodology, as depicted 
in the FBC workflow (figure 2). All five steps of this workflow 
(as described above in the Methods section) were applied to the 
data from the PASTURE/EFRAIM cohort. In order to include 
participants with more missing values (step 3), we analysed the 
stability of the clusters found in the gold standard upon random 
removal of different percentages of measurements. Using suitable 
tolerance levels of cluster disruption, we were able to include 
participants in the analysis that had 20% of their values missing.
The final clustering together with each participant’s individual 
collection of normalised morning FEV1 values are depicted in 
figure 4.
The statistical analysis and characterisation of the clusters 
found is presented in full detail below. The very last subsection 
of the results section is devoted to the statistical analysis and 
characterisation of the clusters found in the BIOAIR cohort. 
There, we carried out the analysis only on the gold standard and 
using whole day measurements of FEV1.
enrichment analysis and clinical characterisation of clusters 
identified in the PAsTure/eFrAIM cohort
We investigated whether the clusters found represent asth-
ma-specific clinical characteristics and phenotypes. More-
over, we looked for potential functional differences among 
Figure 3 Workflow of the method, steps 1–4. (A) Heatmap representation of the matrix of lung function profiles. To the left of the matrix: 
dendrogram resulting from hierarchical clustering. Each row in the matrix corresponds to one participant in the gold standard, a subset of the cohort 
selected thorough quality and compliance criteria. Each entry in the matrix is the result of a distance calculation between a pair of distributions 
of lung function measurements (B). Three identified clusters are marked with colour bars (green, blue and magenta) for illustration purposes. (C) 
Assessment of the stability of the clusters upon random removal of a fixed percentage of measurements. Stability requirements allow for the 
calculation of a tolerable percentage of missing data. The gold standard subset is extended by including participants with a tolerable level of missing 
measurements. A new matrix of lung function profiles is constructed, and hierarchical clustering on those profiles is performed using this extended 
data set (D). Cluster assignment of previous cluster members is visible via colour bars on black background. The data underlying all panels are 
hypothetical normalised PEF values created/selected to illustrate the method. PEF, peak expiratory flow.
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the healthy participants. To this end, we determined whether 
the individual clusters were significantly enriched (see 
Methods and part 2.4 of the OSM) in the following clinical 
phenotypes and characteristics available within the cohort: 
children of farmers versus those of non-farmers, gender, 
atopic disease, asthma diagnosis, recurrent wheeze, episodic 
wheeze, atopic asthma, non-atopic asthma, presence of the 
risk allele containing the SNP rs7216389 in the gasdermin 
B (GSDMB) coding region of chromosome 17q21 (see, 
eg, ref 37), FeNO as a marker of airway inflammation, and 
significant bronchodilator response (see online supplemen-
tary table E1). Results and statistical significance are reported 
in table 1. Results for all variables, time slots and clustering 
multiplicities can be found in online supplementary tables 
S2–S7.
In cluster 1, the mean morning FEV1 measurements tended to 
be lower, which is consistent with more airway obstruction. This 
cluster also displayed the lowest mean coefficient of variation in 
FEV1 values, although the highest SD.
The enrichment analysis unveiled significantly more children 
with clinical symptoms of asthma in clusters 1 and 2. In cluster 1, 
more children with asthma, according to the broader definition, 
lower lung function and positive bronchodilator response but 
no allergic predisposition, were found than expected by chance. 
Cluster 2 was significantly enriched in children with recurrent 
wheezing symptoms and who used inhaled corticosteroids as 
asthma treatment. In contrast to cluster 1, cluster 2 is character-
ised by the highest mean variability in FEV1, which is almost five 
times higher than in cluster 1. Thus, FBC was helpful in iden-
tifying two lung functional phenotypes, each of which contrib-
uting differently to the clinical manifestation of asthma. These 
are namely functionally different in terms of mean, coefficient of 
variation (CV) of daily lung function and in terms of bronchodi-
lator responsiveness, but not in terms of atopy or inflammatory 
markers (FeNO).
Clusters 3 and 4 appeared different and showed the highest 
proportion of healthy participants (>80%). Interestingly, FBC 
similarly separated two functional phenotypes in the healthy 
control participants (clusters 3 and 4) with lung function values 
typically in the normal range. Cluster 3 showed a group low 
mean FEV1 and low variability and was enriched with individ-
uals living in a farming environment. There were significantly 
more participants in cluster 3 (79.6%) who carried the risk allele 
GSDMB rs7216389. Cluster 4 contained predominantly healthy 
children—and more girls than boys—with high normalised mean 
lung function and high mean variability in FEV1. This cluster 
was depleted (ie, fewer than expected by chance) of participants 
carrying the risk allele GSDMB rs7216389.
Clusters 1 and 3 appeared similar with both showing less vari-
able FEV1 and a comparatively low mean FEV1. At the same time, 
cluster 1 was clearly dominated by children with clinical symp-
toms of asthma, whereas cluster 3 corresponded to a healthy 
Figure 4 Dendrogram obtained via hierarchical clustering of each participant’s lung function profile within the subset obtained after extension 
of the gold standard (PASTURE/EFRAIM cohort). The heatmap does not show the participants’ lung function profiles. Instead, each row corresponds 
to one participant and illustrates their individual collection of normalised morning FEV1 values. The different lengths of the rows reflect the 
aforementioned compliance issues within this cohort. The colour bar between the dendrogram and the heatmap indicates the colour-coded country 
of the participants. The random pattern of colours demonstrates that the individual clusters are not enriched in any particular nationality (verified by 
hypergeometric test, results not shown). PASTURE, Protection Against Allergy – Study in Rural Environments.
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subgroup. Thus, the same ‘functional type’ found in individuals 
with asthma can be found to a milder degree in healthy chil-
dren. Moreover, the four clusters were not significantly different 
in terms of the levels of FeNO, and no cluster was enriched in 
atopic individuals.
Independent application using dataset of mild-to-moderate 
and therapy-resistant severe adult asthmatics (bIOAIr cohort)
In order to explore the ability of our method to discriminate 
between different levels of disease severity, we analysed data 
from 138 patients consisting of 76 clinically defined thera-
py-resistant severe asthmatics and 62 mild-to-moderate asth-
matics.33 According to the same criterion defined above, we 
identified the gold standard, which consisted of 45 patients. 
We then conducted hierarchical clustering on the lung func-
tion profiles of these patients and cut the dendrogram at the 
height that yielded two clusters. By means of enrichment 
analysis, we determined that these two clusters separated the 
gold standard into mainly mild-to-moderate asthmatics, on 
the one hand, and predominantly severe asthmatics, on the 
other hand (table 2).
This is particularly interesting since the group mean of 
FEV1 in the clinically defined mild-to-moderate asthmatics 
(median=−2.0, Interquartile interval=(−2.4; −1.4)) showed 
a large overlap with the group of severe asthmatics (−2.8 
(−3.5; −1.6)). Consequently, a classifier solely based on a 
threshold value of mean lung function would frequently yield 
a misclassification. Using the patients’ individual fluctuation 




Both airway inflammation and reversible airway obstruction are 
key features of bronchial asthma in children and adults. Most 
published clustering methods for phenotyping asthma have used 
clinical, inflammatory or lung function markers at a single point 
in time. However, for the clinician in daily practice, the history 
of the day-to-day obstructive response of the airways to external 
stimuli in the patient’s environmental context is crucial in diag-
nosis and treatment decisions. So far, temporal fluctuation of 
daily lung function has never been used to functionally pheno-
type or cluster groups of patients with asthma. By combining 
fluctuation analysis and clustering methods, we present here a 
novel clustering approach to lung functional phenotyping (FBC). 
Moreover, we have developed a procedure that effectively deter-
mines the tolerable number of missing measurements in a data-
driven manner.
Using FBC in the cohort of children, we identified two distinct 
lung functional phenotypes of participants with well-known clin-
ical characteristics of asthma. These were significantly different 
from two functional clusters consisting of mainly healthy infants. 
Mostly non-atopic asthmatics were over-represented in clusters 
1 and 2. Children in the asthma-related clusters 1 and 2 were 
different in their degree of obstruction, bronchodilator respon-
siveness and medication use. While we found a predominance of 
Table 1 Absolute (and relative) number of individuals with the phenotype or characteristic (see online supplementary table E1 for definitions) 
specified in the first column in the different clusters. Enrichment in a given phenotype/characteristic is marked in bold letters. Depletion in a given 
phenotype/characteristic is marked in italics
Morning FeV1 Cluster 1 Cluster 2 Cluster 3 Cluster 4
Cluster size 60 161 54 84
Mean # measurements/participant (min; max) 22.5 (16; 30) 21.5 (16; 29) 21.4 (16; 29) 21.6 (16; 28)
Children of farmers versus of non-farmers (n (%)) 26 (43.3) 68 (42.2) 29**(53.7) 29*(34.5)
Girls versus boys (n (%)) 16****(26.7) 80 (49.7) 26 (48.1) 51***(60.7)
Atopic disease (n (%)) 18 (30) 45 (28) 17 (31.5) 30 (35.7)
Doctor diagnosed asthma (n (%)) 5*(8.3) 9 (5.6) 2 (3.7) 3 (3.6)
Asthma according to broader definition (n (%)) 9**(15) 17 (10.6) 3 (5.6) 5 (6)
Recurrent unremitting wheeze phenotype (n (%)) 5 (8.3) 17*(10.6) 4 (7.4) 4*(4.8)
Unremitting wheeze phenotype (n (%)) 14 (23.3) 28 (17.4) 11 (20.4) 16 (19.0)
Atopic asthma (n (%)) 5 (8.3) 10 (6.2) 3 (5.6) 4 (4.8)
Non-atopic asthma (n (%)) 3*(5.0) 7*(4.3) 0 (0.0) 1 (1.2)
Healthy children (n (%)) 31****(51.7) 125 (77.6) 44 (81.5) 73***(86.9)
Significant bronchodilator response (n (%)) 15**(25.0) 31 (19.3) 10 (18.5) 10 (11.9)
Use of inhaled corticosteroids (n (%)) 3 (5.0) 11**(6.8) 1 (1.9) 3 (3.6)
Mean FeNO (ppb) 9.898 10.108 11.427 9.828
Presence of risk allele GSDMB rs7216389 (n (%)) 41 (68.3) 112 (69.6) 43**(79.6) 52*(61.9)
Average of mean normalised FEV1 (z-score) −2.574**** −0.525**** −1.385**** 0.631****
Mean coefficient of variation of normalised FEV1 0.566**** 2.765**** 0.681**** 2.183****
Mean SD of normalised FEV1 1.240*** 0.867 0.897 0.865
Significance levels of the hypergeometric test (Mann-Whitney test when comparing FeNO, and means, SD and coefficients of variation of normalised FEV1 values) are *p<0.1, 
**p<0.05, ***p<0.01 and ****p<0.001. As every participant has their own collection of lung function measurements, the mean, the SD and the coefficient of variation of FEV1 
(or of PEF) can be calculated for each individual participant. However, in order to characterise a given cluster, the average of the means, the mean SD and the mean coefficient 
of variation among all cluster members were calculated (three bottom rows). The average of the means is not the pooled mean. Rather, it is the mean of the distribution of mean 
lung function among the members of a given cluster. The data underlying the cluster identification are normalised morning FEV1values from the PASTURE/EFRAIM cohort. 
FeNO, fraction of exhaled nitric oxide; PASTURE, Protection Against Allergy – Study in Rural Environments; PEF, peak expiratory flow.
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children with good β2 response in cluster 1, more children were 
treated with inhaled corticosteroids in cluster 2. Interestingly, in 
cluster 1, we found asthmatic children with low lung function, 
low variability and significant bronchodilator response, whereas 
in cluster 2, mean FEV1 was higher and accompanied by high 
daily variability.
Similarly, in the predominantly healthy clusters (3 and 4), 
cluster 3 was characterised by low-normal mean FEV1 and low 
variability, whereas 4 showed high mean FEV1, higher natural 
fluctuations of FEV1 and a predominance of girls. In fact, we 
found the functional phenotypes characterised by low mean and 
low variability, as well as the functional phenotypes characterised 
by high mean and high variability in asthma, but also to a milder 
degree in predominantly healthy children (clusters 1 and 3, 
and clusters 2 and 4, respectively). Since inflammatory markers 
(atopic predisposition and FeNO) were not different between 
these four clusters, our data suggest that FBC identifies dynamic 
lung functional characteristics of the airways in response to the 
given environment, at least partially independent of their atopic 
and inflammatory status.
Our data also suggest that intrinsic hereditary and inter-
acting environmental factors may contribute to asthma and, 
to a milder degree, to healthy phenotypes. Hereditary effects, 
such as sex effects (clusters 1 and 4), and also associations with 
asthma-related genes (17q21) were observed in clusters 3 and 
4. In cluster 3, we found an enrichment of children carrying 
the risk allele containing the SNP rs7216389 in the gasdermin 
B (GSDMB) coding region of chromosome 17q21, and in cluster 
4, a depletion of such individuals. The presence of this allele has 
been linked to asthma, exacerbation risk and changes in FEV1. 
In particular, specific associations with bronchial hyper-respon-
siveness, severe asthma and asthma that is poorly controlled by 
current medications have been found (see ref 37 and the citations 
therein). The association of rs7216389 with exacerbation risk, 
bronchial responsiveness38 and also gene interactions with argi-
nase1 (rs37756780, ARG1)39 may be a potential underlying 
mechanism to explain the enrichment and depletion of SNP 
rs7216389 in clusters 3 and 4, respectively. Moreover, recently, 
a gene-by-environment interaction of locus 17q21 has been 
demonstrated.40 In particular, it has been shown that individ-
uals carrying the GSDMB rs7216389 variant particularly benefit 
from growing up in a farming environment due to its protective 
effect against virus-induced wheeze and non-atopic asthma. In 
cluster 3, children living in a farming environment were predom-
inant. Their vulnerability resulting from carrying the risk allele 
GSDMB rs7216389 is thus compensated via the aforementioned 
protective effect. This may explain why the comparatively 
reduced lung function that is strikingly characteristic of the chil-
dren in cluster 3 generally remains asymptomatic. Nevertheless, 
temporal variations of environmental triggers41 in the farming 
environment may particularly affect daily lung function.
Our results indicate that our methodology may be useful for 
phenotyping in existing asthma and also for functional pheno-
typing in healthy individuals. For instance, our findings regarding 
cluster 3 suggest that this cluster could potentially contain a 
subgroup of individuals at risk of developing asthma. Future 
longitudinal studies will be required in order to investigate this.
In our second cohort (BIOAIR), we found that our FBC 
method was able to discriminate between mild-to-moderate 
asthma and therapy-resistant severe asthma. Our findings are 
consistent with previous observations that fluctuation patterns 
in severe asthma are different than in mild asthmatics.26
Our method is based on distribution but not correlation prop-
erties of the lung function measurements. Calculating correla-
tion from data with missing data points is prone to errors. Thus, 
while neglecting the time dimension, we gain robustness with 
respect to missing data, which increases the feasibility and clin-
ical applicability of the method.
Limitations and advantages of the FBC method, especially in 
comparison with other existing clustering approaches to disease 
phenotyping, are discussed in the OSM.
Clinical implications of this novel approach
FBC identifies two distinct clusters of asthma patients and two 
clusters of healthy participants with specific dynamic lung func-
tional interaction patterns to the stimuli in their given environ-
ment, which is at least partly independent of the inflammatory 
or atopic status, but may be related to hereditary (sex, 17q21 
(GSDMB)) and environmental factors (eg, farming). We believe 
that lung functional stability over an extended window of time 
is an additional and important characteristic to be considered 
in asthma research and is different from a single-point-in-time 
characterisation. This is particularly important since it becomes 
increasingly evident that many asthma biomarkers need to be 
interpreted within the context of the patient’s given environ-
ment. We hypothesise that these dynamic lung functional char-
acteristics are relevant for the understanding of disease stability 
over time and also for the search for treatable traits.
There is increasing evidence that the causal relation between 
airway inflammation and subsequent airway obstruction is weak 
and complex. Lung functional impairment, smooth muscle 
mechanics21 and impaired elastic recoil of the airways in obese 
patients42 can contribute to airway obstruction and asthma symp-
toms independent of airway inflammation.8 As demonstrated 
in the BADGER study,29 some patients may benefit more from 
bronchodilator therapy than from step-up anti-inflammatory 
Table 2 Absolute (and relative) number of individuals with the 
phenotype or characteristic specified in the first column in the different 
clusters. Enrichment (hypergeometric test) in a given phenotype/
characteristic is marked in bold letters
Cluster 1 Cluster 2
Number of patients 28 17
  Mean # measurements/participant 
(min; max)
575 (477; 708) 574 (481; 706)
Airway disease
  Mild-to-moderate asthma (n (%)) 17 (60.7)*** 5 (29.4)
  Severe asthma (n (%)) 11 (39.3) 12 (70.6)***
  Average of mean normalised FEV1 
(z-score)
−1.7**** −3.6****
  Mean coefficient of variation of 
normalised FEV1
0.430**** 0.217****
  Mean SD of normalised FEV1 0.5 0.6
Significance levels of the hypergeometric test (Mann-Whitney test when comparing 
means, SD and coefficients of variation of normalised FEV1 values) are *p<0.1, 
**p<0.05, ***p<0.01 and ****p<0.001. As every participant has their own 
collection of lung function measurements, the mean, the SD and the coefficient 
of variation of FEV1 (or of PEF) can be calculated for each individual participant. 
However, in order to characterise a given cluster, the average of the means, the 
mean SD and the mean coefficient of variation among all cluster members were 
calculated (three bottom rows). The average of the means is not the pooled mean. 
Rather, it is the mean of the distribution of mean lung function among the members 
of a given cluster. The data underlying the cluster identification are normalised 
twice-a-day FEV1values from the BIOAIR cohort.
BIOAIR, Pan-European Longitudinal Assessment of Clinical Course and BIOmarkers 
in Severe Chronic AIRway Disease.
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treatments in order to achieve asthma stability. FBC might help 
identify such patients. Future studies will need to demonstrate 
whether FBC phenotyping (eg, cluster 1) may contribute to this 
clinical decision making. Previous work has already shown that 
lung function fluctuation patterns can predict treatment response 
to long-acting β-agonists.28 Within the context of adult asthma, 
the method contributes to the identification of severe thera-
py-resistant asthmatic patients, a known distinct entity, which is 
typified by a lack of asthma control despite appropriate anti-in-
flammatory treatment. In these patients, not only steroid resis-
tance, but also airway remodelling and fixed functional airway 
impairment contribute to poor asthma control. In such cases, 
FBC could help identify patients with lung mechanical impair-
ment. FBC does not replace other clustering methods but as a 
complementary method could provide evidence of mechanical 
impairment by way of measurements taken in a telemonitoring 
setting.
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